> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Wins EU Committee Backing For Blood-Pressure Drug Already Approved In The US
- URL: https://www.bullished.co/astrazeneca-wins-eu-committee-backing-for-blood-pressure-drug-already-approved-in-the-us-2a487688/
- Published: 2026-11-16T12:26:56.000Z
- Updated: 2026-11-16T12:26:56.000Z
- Description: Baxfendy could become the EU's first aldosterone synthase inhibitor for patients whose blood pressure remains uncontrolled on other medicines.
- Author: Matteo Parrino
- Tags: SEC Filings, AZN, Industry: Healthcare

[AstraZeneca](https://www.bullished.co/tag/azn/), which develops and sells prescription medicines and vaccines, won an EU medicines committee's [recommendation for approval](https://www.sec.gov/Archives/edgar/data/901832/000165495426009815/a2430d.htm?ref=bullished.co) Monday for Baxfendy, its blood-pressure drug already approved in the US. The company's announcement said the proposed use covers adults whose hypertension remains insufficiently controlled on at least two medicines.

## A New Route To Lower Pressure

Baxfendy, also called baxdrostat, blocks aldosterone synthase, the enzyme involved in making aldosterone. That hormone promotes salt and water retention and can raise blood pressure; elevated levels are associated with kidney damage and cardiovascular risk.

The European Medicines Agency's Committee for Medicinal Products for Human Use gave the positive opinion. AstraZeneca said approval would make Baxfendy the EU's first and only medicine in this class.

About 70 million adults in Europe have high blood pressure that remains uncontrolled despite treatment. Worldwide, hypertension affects an estimated 1.4 billion people, and approximately 50% of patients taking at least two blood-pressure medicines still struggle to control it.

## Two Trials, Different Pressure Readings

The recommendation rests on late-stage studies testing Baxfendy alongside patients' existing treatment. In the 796-patient clinic-measurement trial, the 2mg daily dose lowered systolic pressure—the upper blood-pressure reading—by 15.7 mmHg from baseline at week 12\. The reduction beyond placebo was 9.8 mmHg.

The separate 218-patient study measured average pressure across 24 hours in people with resistant hypertension, meaning pressure remained elevated despite at least three medicines. The 2mg dose produced a 16.6 mmHg reduction from baseline and a 14.0 mmHg reduction beyond placebo at week 12.

In that study, 70.6% of Baxfendy patients reached a 24-hour average systolic reading below 130 mmHg, versus 16.7% receiving placebo. AstraZeneca said reductions persisted across the day, including early morning, and that both trials showed generally good tolerability without unexpected safety findings.

Bryan Williams, Chair of Medicine at University College London and primary investigator for both trials, said: "Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a [roughly 20%](https://www.sec.gov/Archives/edgar/data/901832/000165495426009815/a2430d.htm?ref=bullished.co) lower risk of serious cardiovascular events like heart attack and stroke, underscoring why effective blood pressure lowering matters for people living with uncontrolled hypertension."

## From CinCor To A Broader Programme

AstraZeneca obtained Baxfendy through its [February 2023 purchase](https://www.sec.gov/Archives/edgar/data/901832/000165495426009815/a2430d.htm?ref=bullished.co) of CinCor Pharma. Alongside its US and other-country approvals, applications remain under review in Japan and China.

The medicine fits AstraZeneca's cardiovascular, kidney and metabolic disease business. The Cambridge, United Kingdom-based company also sells cancer treatments including Imfinzi, Tagrisso and Enhertu, as well as the diabetes and kidney medicine Farxiga/Forxiga.

AstraZeneca is studying Baxfendy alone for primary aldosteronism and with dapagliflozin for chronic kidney disease and hypertension, as well as heart-failure prevention in patients with hypertension.

The EU committee's recommendation brings Baxfendy closer to approval for patients whose existing medicines have not adequately controlled their blood pressure; approval itself remains pending.

### Sources

- [Form 6-K — BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU](https://www.sec.gov/Archives/edgar/data/901832/000165495426009815/a2430d.htm?ref=bullished.co) — SEC EDGAR
- [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://finance.yahoo.com/healthcare/articles/astrazeneca-gets-us-nod-expanded-080206700.html?ref=bullished.co) — Reuters

### More on AstraZeneca

- [AstraZeneca Wins Bladder Cancer Approval After Imfinzi Regimen Cuts Death Risk 42% In Trial](https://www.bullished.co/astrazeneca-wins-bladder-cancer-approval-after-imfinzi-regimen-cuts-death-risk-42-in-trial-2d4bb564/)
- [AstraZeneca Wins EU Approval For Klygefa, Adding A Weekly Self-Injection Option](https://www.bullished.co/astrazeneca-wins-eu-approval-for-klygefa-adding-a-weekly-self-injection-option-15b39365/)
- [AstraZeneca Stock Soars 7%, Adding $20 Billion, As Cancer Drugs Lift Quarterly Profit](https://www.bullished.co/astrazeneca-stock-soars-7-adding-20-billion-as-cancer-drugs-lift-quarterly-profit-66c1ed74/)

[All AstraZeneca (AZN) coverage →](https://www.bullished.co/tag/azn/)